The landscape of pediatric and adult hematological oncology is undergoing a significant shift as specialized immunotherapies and targeted molecular treatments replace traditional non-specific regimens. The Acute Lymphocytic Lymphoblastic Leukemia (ALL) Therapeutics Market was valued at USD 1.36 billion in 2024 and is expected to reach USD 2.41 billion by 2032,...